정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 555 | Completed | Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC) | COVID-19 | Drug: Sargramostim Other: Control |
Phase 4 | University Hospital, Ghent, Flanders Institute of Biotechnology | OTHER | 80 | All | 18 Years ~ 80 Years | AZ Sint Jan Brugge, Brugge, Belgium University Hospital Ghent, Gent, Belgium UZ Brussel, Jette, Belgium AZ Delta Roeselare, Roeselare, Belgium |
| 554 | Recruiting | Sargramostim Use in COVID-19 to Recover Patient Health | SARS-CoV Infection | Drug: Sargramostim Drug: Placebo |
Phase 2 | Partner Therapeutics, Inc., United States Department of Defense | INDUSTRY | 500 | All | 18 Years | West Valley Research Clinic, LLC, Phoenix, Arizona, United States Applied Research Center of Arkansas, Little Rock, Arkansas, United States Hope Clinical Research, Canoga Park, California, United States Benchmark Research, Colton, California, United States Synergy Healthcare, Bradenton, Florida, United States Invesclinic US, LLC., Fort Lauderdale, Florida, United States Indago Research & Health Center, Inc. (Subject Visits Only), Hialeah, Florida, United States Encore Medical Research, Hollywood, Florida, United States IMIC Inc., Palmetto Bay, Florida, United States Encore Medical Research of Weston, Weston, Florida, United States Gwinnett Research Institute, LLC, Buford, Georgia, United States Paramount Research Solutions, College Park, Georgia, United States TidalHealth Peninsula Regional, Inc., Salisbury, Maryland, United States Revive Research Institute, Inc., Farmington Hills, Michigan, United States Revival Research Institute, LLC., Sterling Heights, Michigan, United States Olive Branch Family Medical Center, Olive Branch, Mississippi, United States Great Plains Health, North Platte, Nebraska, United States Excel Clinical Research, Las Vegas, Nevada, United States Richmond University Medical Center, Staten Island, New York, United States Monroe Biomedical Research, Monroe, North Carolina, United States Hometown Urgent Care and Research, Cincinnati, Ohio, United States Hometown Urgent Care and Research, Columbus, Ohio, United States Urgent Care Specialists, LLC DBA Hometown Urgent Care and Research, Dayton, Ohio, United States Urgent Care Clinical Trials @ AFC Urgent Care - Easley, Easley, South Carolina, United States University Diabetes & Endocrine Consuttants, Chattanooga, Tennessee, United States UCCT @ City Doc Urgent Care-McKinney, Dallas, Texas, United States Invesclinic US LLC, Edinburg, Texas, United States Dorrington Medical Associates, Houston, Texas, United States Encore Imaging & Medical Research, Houston, Texas, United States SMS Clinical Research, LLC, Mesquite, Texas, United States Novotrial Research Group, Pearland, Texas, United States Sun Research Institute, San Antonio, Texas, United States University of Utah Health, Salt Lake City, Utah, United States Sanatorio Santa Barbara, Buenos Aires, Argentina |
| 553 | Completed | Sarilumab COVID-19 | Corona Virus Infection | Drug: Sarilumab SAR153191 Drug: Placebo |
Phase 3 | Sanofi, Regeneron Pharmaceuticals | INDUSTRY | 420 | All | 18 Years | Investigational Site Number 0320001, Caba, Argentina Investigational Site Number 0320003, Caba, Argentina Investigational Site Number 0320004, Caba, Argentina Investigational Site Number 0760003, Porto Alegre, Brazil Investigational Site Number 0760001, Sao Paulo, Brazil Investigational Site Number 0760002, Sao Paulo, Brazil Investigational Site Number 0760004, Sao Jose Do Rio Preto, Brazil Investigational Site Number 0760005, Sao Paulo, Brazil Investigational Site Number 1240001, Montreal, Canada Investigational Site Number 1240005, Montreal, Canada Investigational Site Number 1240004, Toronto, Canada Investigational Site Number 1240002, Toronto, Canada Investigational Site Number 1240003, Vancouver, Canada Investigational Site Number 1520003, Santiago, Chile Investigational Site Number 1520002, Santiago, Chile Investigational Site Number 1520004, Santiago, Chile Investigational Site Number 1520001, Talca, Chile Investigational Site Number 2500001, Bordeaux Cedex, France Investigational Site Number 2500007, Clamart, France Investigational Site Number 2500006, La Roche Sur Yon Cedex 9, France Investigational Site Number 2500002, Nantes, France Investigational Site Number 2500005, Paris Cedex 18, France Investigational Site Number 2500003, Strasbourg, France Investigational Site Number 2500004, Suresnes, France Investigational Site Number 2760002, Essen, Germany Investigational Site Number 2760004, Koln, Germany Investigational Site Number 2760001, Munster, Germany Investigational site number 3760003, Ashdod, Israel Investigational Site Number 3760002, Jerusalem, Israel Investigational Site Number 3760001, Ramat Gan, Israel Investigational Site Number 3800005, Milano, Italy Investigational Site Number 3800001, Milano, Italy Investigational Site Number 3800002, Milano, Italy Investigational Site Number 3800003, Modena, Italy Investigational Site Number 3800004, Parma, Italy Investigational Site Number 3800006, Rozzano, Italy Investigational Site Number 3920002, Fuchu-Shi, Japan Investigational Site Number 3920003, Iruma-Gun, Japan Investigational Site Number 3920001, Kamakura-Shi, Japan Investigational Site Number 6430003, Moscow, Russian Federation Investigational Site Number 6430002, Moscow, Russian Federation Investigational Site Number 6430001, Moscow, Russian Federation Investigational Site Number 7240003, Barcelona, Spain Investigational Site Number 7240004, Barcelona, Spain Investigational Site Number 7240002, Madrid, Spain Investigational Site Number 7240005, Madrid, Spain Investigational Site Number 7240001, Madrid, Spain |
| 552 | Active, not recruiting | Sarilumab for Patients With Moderate COVID-19 Disease | COVID | Biological: SARILUMAB | Phase 2 | Westyn Branch-Elliman | FED | 50 | All | 18 Years | VA Connecticut Healthcare System, West Haven, Connecticut, United States VA Maine Healthcare System, Augusta, Maine, United States VA Boston Healthcare System, Boston, Massachusetts, United States Providence VA Medical Center, Providence, Rhode Island, United States VA Medical Center - White River Junction, White River Junction, Vermont, United States |
| 551 | Recruiting | Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19 | COVID-19 Drug Treatment | Drug: Sarilumab | Phase 2 | Clinica Universidad de Navarra, Universidad de Navarra, Sanofi, Hospital Universitario Infanta Leonor | OTHER | 60 | All | 18 Years | Clinica Universidad de Navarra, Universidad de Navarra, Pamplona, Navarra, Spain Hospital Universitario Infanta Leonor, Madrid, Spain |
| 550 | Completed | SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients | COVID-19 | Biological: SARS-CoV-2 antibody based IVIG therapy | Phase 2 | Dow University of Health Sciences, Higher Education Commission (Pakistan) | OTHER | 50 | All | 18 Years | Dow University of Health Sciences, Karachi, Sindh, Pakistan |
| 549 | Not yet recruiting | SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease | Covid19 | Other: Standard of Care Biological: SARS-CoV2-CTLS |
Phase 2 | New York Medical College, Children's Hospital of Philadelphia, Medical College of Wisconsin, Nationwide Children's Hospital | OTHER | 50 | All | 18 Years ~ 65 Years | Nationwide Children's Hosptial, Columbus, Ohio, United States Children's Hospital of Pennsylvania, Philadelphia, Pennsylvania, United States Medical College of Wisconsin/Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States |
